Human sCD21 ELISA kit

In this study, we develop a sensitive indirect competitive chemiluminescent enzyme immunoassay (ic-CLEIA) to detect cadmium (Cd) in cereals. A luminol-hydrogen peroxide chemiluminescence system catalysed by horseradish peroxidase (HRP) was used as the signal detecting system. The method showed a half-maximal inhibition concentration (IC50) of 0.5 ng/mL and a limit of determination (LOD) of 0.06 ng/mL. The assay indicated an effective linear range from 0.16 to 1.56 ng/mL. There were no obvious cross-reactivities with other metal ions, including Hg2+, Pb2+, As2+, Ag+, Fe3+, Cu2+, Cr2+, Au3+, Ca2+, Mg2+, Mn2+ and Zn2+. Recovery rates ranged from 79.2% to 120.0% for rice, maize, wheat, brown rice and glutinous rice samples. Twenty-five practical cereal samples were analysed, and the comparative analysis of the results showed a strong correlation (r = 0.984) between the CLEIA and the GFAAS methods. The results indicated that the ic-CLEIA developed was acceptable to screen for cadmium in cereal samples. [GRAPHICS]

Background: T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and improve survival, but data is limited. Patients and methods: We evaluated clinical outcomes of 11 patients, median age of 56 (range, 43-71) years who underwent allo-HCT for T-PLL. The majority of cases were in the first complete remission (CR1=9, CR2=1, second partial response PR2=1) at time of allo-HCT. Myeloablative conditioning was the most commonly prescribed preparative regimen (n=8, 73%) and tacrolimus plus sirolimus was most commonly prescribed regimen for graft-versus-host disease prophylaxis (n=5, 46%). Results: The median follow-up for surviving patients was 48 (range, 6-123) months. The 4-year progression-free survival (PFS) and overall survival (OS) were 45% (95% confidence interval (CI)=13-78%) and 56% (95% CI=24-89%), respectively. Cumulative incidence of non-relapse mortality (NRM) at 4-year post-transplantation was 34% (95% CI=14-85%). The 4-year cumulative incidence of relapse/progression was 21% (95% CI=6-71%). Conclusion: Allo-HCT is an effective treatment for T-PLL. Patients must be evaluated for their candidacy for allo-HCT as soon as the diagnosis is confirmed. Efforts are needed to decrease NRM and relapse.